The 21Shares XRP exchange-traded fund is now approved for listing on Cboe BZX Exchange, marking a key step before trading begins. The new fund will join several other XRP ETFs which have already gained significant traction. Cboe confirmed the approval…The 21Shares XRP exchange-traded fund is now approved for listing on Cboe BZX Exchange, marking a key step before trading begins. The new fund will join several other XRP ETFs which have already gained significant traction. Cboe confirmed the approval…

Cboe BZX approves listing of 21Shares spot XRP ETF

2025/12/11 11:58
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The 21Shares XRP exchange-traded fund is now approved for listing on Cboe BZX Exchange, marking a key step before trading begins.

Summary
  • Cboe approves the listing of the 21Shares XRP ETF under ticker TOXR.
  • The fund uses multi-custody storage and a 0.3% sponsor fee paid in XRP.
  • XRP ETFs near $1 billion in assets as inflows continue to build.

The new fund will join several other XRP ETFs which have already gained significant traction.

Cboe confirmed the approval in a Dec. 10 filing with the Securities and Exchange Commission, which certifies that the exchange is ready to list and register the fund once official issuance notices are complete. The ETF will track the CME CF XRP-Dollar Reference Rate – New York Variant, giving investors regulated access to XRP (XRP) price exposure without handling the asset directly.

Key ETF structure and market setup

The move comes three weeks after the SEC’s automatic approval of 21Shares’ 8-A registration, which followed the firm’s amended S-1 submission.

While the Dec. 8 S-1/A remains marked “Subject to Completion,” regulators consider this a procedural label that does not block exchange listing. Trading could begin as early as next week, depending on final administrative steps.

The 21Shares XRP ETF carries a 0.3% annual sponsor fee, calculated daily and paid weekly in XRP. The product uses a multi-custodian model with Coinbase Custody, Anchorage Digital Bank, and BitGo Trust Company managing the fund’s physical XRP reserves.

Ripple Markets seeded the ETF with 100 million XRP, worth roughly $226 million at current prices. Shares will be created or redeemed in-kind through XRP transfers or in cash by authorized participants.

The ETF will trade on the Cboe BZX Exchange under the ticker TOXR, placing it alongside other digital-asset products that have recently launched on the venue.

Impact on the growing XRP ETF market

The approval strengthens a market that has expanded rapidly following the SEC–Ripple lawsuit settlement earlier this year, which affirmed that XRP is not a security in secondary sales. Launched in late November, several spot XRP ETFs have reached milestones at a rate not seen since the initial Ethereum ETFs. 

As of Dec. 11, at least four spot XRP ETFs are active, with combined assets nearing $1 billion and net inflows above $900 million since inception. Analysts view the 21Shares product as a key addition, especially given its size, seed capital, and custody design.

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.3669
$1.3669$1.3669
+0.76%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09